MicroRNAs Associated with Metastatic Prostate Cancer

Watahiki, Akira; Wang, Yuwei; Morris, James; Dennis, Kristopher; O’Dwyer, Helena; Gleave, Martin; Gout, Peter W.; Wang, Yuzhuo

doi:10.1371/journal.pone.0024950

Cited by 187 publications

(157 citation statements)

References 79 publications

(123 reference statements)

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Similar to the association we observed for miR339-5p, higher expression was associated with lower metastasis rates, and in addition reduced cancer cell growth and better patient survival in breast cancer (49). Also for prostate cancer, lower expression of miR339-5p was observed in metastatic cancer (50).…”

Section: Discussionsupporting

confidence: 84%

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Colon cancer prognosis and treatment are currently based on a classification system still showing large heterogeneity in clinical outcome, especially in TNM stages II and III. Prognostic biomarkers for metastasis risk are warranted as development of distant recurrent disease mainly accounts for the high lethality rates of colon cancer. miRNAs have been proposed as potential biomarkers for cancer. Furthermore, a verified standard for normalization of the amount of input material in PCR-based relative quantification of miRNA expression is lacking.Methods: A selection of frozen tumor specimens from two independent patient cohorts with TNM stage II-III microsatellite stable primary adenocarcinomas was used for laser capture microdissection. Next-generation sequencing was performed on small RNAs isolated from colorectal tumors from the Dutch cohort (N ¼ 50). Differential expression analysis, comparing in metastasized and nonmetastasized tumors, identified prognostic miRNAs.

show abstract

Section: Discussionsupporting

confidence: 84%

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Two recent studies reported increased serum levels of miR-375 (and miR-141) in patients with metastatic prostate carcinoma (26,27). In contrast, a miRNA profiling approach based on high-throughput sequencing by Watahiki and colleagues did not find an increase of miR-375 in metastatic prostate carcinoma (28). Other studies using microarray analysis also did not find an induction of miR-375 in prostate carcinoma (reviewed in refs.…”

Section: Discussionmentioning

confidence: 99%

Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing

Hart

Nolte

Wach

et al. 2014

Molecular Cancer Research

View full text Add to dashboard Cite

MicroRNAs (miRNA) posttranscriptionally regulate gene expression and are important in tumorigenesis. Previous deep sequencing identified the miRNA profile of prostate carcinoma versus nonmalignant prostate tissue. Here, we generated miRNA expression profiles of prostate carcinoma by deep sequencing, with increasing tumor stage relative to corresponding nonmalignant and healthy prostate tissue, and detected clearly changed miRNA expression patterns. The miRNA profiles of the healthy and nonmalignant tissues were consistent with our previous findings, indicating a high fidelity of the method employed. In the tumors, quantitative real-time PCR (qRT-PCR) analysis of 40 paired samples of prostate carcinoma versus normal tissue revealed significant upregulation of miR-20a, miR-148a, miR-200b, and miR-375 and downregulation of miR-143 and miR-145. Hereby, miR-375 increased from normal to organ-confined tumors (pT2 pN0), slightly decreased in tumors with extracapsular growth (pT3 pN0), but was then expressed again at higher levels in lymph node metastasizing (pN1) tumors. The sequencing data for miR-375 were confirmed by Northern blotting and qRT-PCR. The regulation for other selected miRNAs could, however, not be confirmed by qRT-PCR in individual tumor stages. MiR-200b, in addition to miR-200c and miR-375 reduced the expression of SEC23A. Interestingly, miR-375, found by sequencing in pT2 upregulated by us and others in tumor versus normal tissue, and miR-15a, found by sequencing in pT2 and pT3 and in the metastasizing tumors, target the phosphatases PHLPP1 and PHLPP2, respectively. PHLPP1 and PHLPP2 dephosphorylate members of the AKT family of signal transducers, thereby inhibiting cell growth. Coexpression of miR-15a and miR-375 resulted in downregulation of PHLPP1/2 and strongly increased prostate carcinoma cell growth.Implications: These genomic data reveal relevant miRNAs in prostate cancer that may have biomarker and therapeutic potential. Mol Cancer Res; 12(2); 250-63. Ó2013 AACR. IntroductionProstate carcinoma is the second most frequently diagnosed malignancy and a leading cause of cancer-related death in men worldwide (1). The underlying mechanisms resulting in invasive growth after dissemination of the primary tumor from the initial site in the prostate are not completely understood. MicroRNAs (miRNAs) are now recognized as contributing factors to the induction, growth, and metastasis

show abstract

“…Furthermore, miR-205 was shown to be downregulated in advanced-stage PCa in our studies (Figure 1a and 1b) and to be down-regulated in metastatic PCa. 23 Chung et al 24 reported that the aberrant expression of miR-205 took place in advanced stages in endometrial cancer. In addition, previous studies have shown that the level of miR-205 was inversely correlated with PSA and tumor stage.…”

Section: Mir-205 Suppresses Tumor Growth In Vivomentioning

confidence: 99%

miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth

Wang¹,

Li²,

Feng³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

The purpose of this study was to elucidate the molecular mechanisms of microRNA-205 (miR-205) as a tumor suppressor in prostate cancer (PCa). In the present study, microRNA microarray analysis suggested that the expression of miR-205 was significantly decreased in advanced PCa compared with early PCa. Real-time PCR analysis also indicated that miR-205 expression was significantly decreased in PCa tissues compared with non-cancerous tissues. Moreover, the expression of miR-205 has been demonstrated to be associated with the clinicopathological stage and total/free prostate-specific antigen (PSA) level of PCa. Functional analyses showed that both the overexpression of miR-205 and the knockdown of c-SRC in PCa cell lines could inhibit cell growth, colony formation, migration, invasion and the cell cycle as well as induce cell apoptosis in vitro. Furthermore, over-expressing miR-205 reduced tumorigenicity in vivo. Through a luciferase activity assay and Western blotting, c-SRC was identified as a target of miR-205 in cells. The overexpression of miR-205 suppressed c-SRC and its downstream signaling molecules, including FAK, p-FAK, ERK1/2 and p-ERK1/2, and attenuated cell proliferation, invasion and tumor growth.

show abstract

MicroRNAs Associated with Metastatic Prostate Cancer

Cited by 187 publications

References 79 publications

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing

miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth

Contact Info

Product

Resources

About